Evidence map›Paper›PMID 26988550›Full record

ArticleBMC genomics2016

A method for near full-length amplification and sequencing for six hepatitis C virus genotypes.

Rowena A Bull, Auda A Eltahla, Chaturaka Rodrigo, Sylvie M Koekkoek, Melanie Walker, Mehdi R Pirozyan, Brigid Betz-Stablein, Armin Toepfer, Melissa Laird, Steve Oh and 5 more

Abstract read
In one paragraph

Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rowena A BullSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia. r.bull@unsw.edu.au.
Auda A EltahlaSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Chaturaka RodrigoSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Sylvie M KoekkoekDepartment of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Public Health Service, Amsterdam, The Netherlands.
Melanie WalkerSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Mehdi R PirozyanSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Brigid Betz-StableinSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Armin ToepferPacific Biosciences, Menlo Park, CA, USA.
Melissa LairdPacific Biosciences, Menlo Park, CA, USA.
Steve OhPacific Biosciences, Menlo Park, CA, USA.
Cheryl HeinerPacific Biosciences, Menlo Park, CA, USA.
Lisa MaherThe Kirby Institute, University of New South Wales, Sydney, Australia.
Janke SchinkelDepartment of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Public Health Service, Amsterdam, The Netherlands.
Andrew R LloydSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Fabio LucianiSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, 2052, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) is a rapidly evolving RNA virus that has been classified into seven genotypes. All HCV genotypes cause chronic hepatitis, which ultimately leads to liver diseases such as cirrhosis. The genotypes are unevenly distributed across the globe, with genotypes 1 and 3 being the most prevalent. Until recently, molecular epidemiological studies of HCV evolution within the host and at the population level have been limited to the analyses of partial viral genome segments, as it has been technically challenging to amplify and sequence the full-length of the 9.6 kb HCV genome. Although recent improvements have been made in full genome sequencing methodologies, these protocols are still either limited to a specific genotype or cost-inefficient.

resultsIn this study we describe a genotype-specific protocol for the amplification and sequencing of the near-full length genome of all six major HCV genotypes. We applied this protocol to 122 HCV positive clinical samples, and had a successful genome amplification rate of 90%, when the viral load was greater than 15,000 IU/ml. The assay was shown to have a detection limit of 1-3 cDNA copies per reaction. The method was tested with both Illumina and PacBio single molecule, real-time (SMRT) sequencing technologies. Illumina sequencing resulted in deep coverage and allowed detection of rare variants as well as HCV co-infection with multiple genotypes. The application of the method with PacBio RS resulted in sequence reads greater than 9 kb that covered the near full-length HCV amplicon in a single read and enabled analysis of the near full-length quasispecies.

conclusionsThe protocol described herein can be utilised for rapid amplification and sequencing of the near-full length HCV genome in a cost efficient manner suitable for a wide range of applications.

Indexed as

Genome, ViralCoinfectionGenotypeHepacivirusHepatitis CHumansLimit of DetectionNucleic Acid Amplification TechniquesPhylogenyRNA, ViralSequence Analysis, DNAViral LoadRNA, Viral

Identifiers

PMID26988550
PMCPMC4797172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.